[Evaluation of therapeutic coverage of mass treatment campaign against lymphatic filariasis in two health districts in Burkina Faso].
Évaluation de la couverture thérapeutique de la campagne de traitement de masse contre la filariose lymphatique dans deux districts sanitaires au Burkina Faso.
Burkina Faso
Directly observed treatment
Fada N'Gourma
Health district
Lymphatic filariasis
Mass treatment
Preventive chemotherapy
Sub-Saharan Africa
Tenkodogo
Therapeutic coverage
Journal
Medecine tropicale et sante internationale
ISSN: 2778-2034
Titre abrégé: Med Trop Sante Int
Pays: France
ID NLM: 9918227363206676
Informations de publication
Date de publication:
31 12 2022
31 12 2022
Historique:
received:
08
11
2021
accepted:
29
11
2022
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
25
2
2023
Statut:
epublish
Résumé
Burkina Faso has been implementing preventive chemotherapy against lymphatic filariasis since 2001. While 61 health districts (HDs) have stopped mass drug administration (MDA), transmission persists in 9 HDs despite good reported MDA coverage. To validate the reported coverage, an independent post-MDA survey was conducted in Tenkodogo and Fada N'Gourma HDs in September 2018. The study population consisted of all persons in the visited communities. The Coverage survey sample builder (CSSB) tool was used to calculate the sample size and to conduct the random selection of households. A total of 30 villages per HD were selected. The investigators were Ministry of Education agents and health workers not involved in MDA. Data were collected on smartphones through the KoBoCollect application regarding age, sex, drug ingestion (ivermectin + albendazole), adverse events, and whether respondents understood MDA guidelines. Stata Version 14 software was used for data analysis. A total of 3,741 individuals were surveyed, 53.3% were female and the median age was 14 years. Surveyed epidemiological coverage was 74% [95% CI: 72-76.1] in Fada N'Gourma and 79.1% [95% CI: 77.2-80.9] in Tenkodogo, compared to reported coverages of 82.6% and 83% respectively. Village-level coverage ranged from 32.9% to 100% in Fada N'Gourma and from 56.7% to 93.3% in Tenkodogo. In total, 99% of those treated said they had swallowed the drugs in front of the community drug distributor (CDD) and confirmed the use of dose poles. The main reasons for non-treatment were non-visitation of the compound by CDD (54%) and absences during MDA (43%). Results showed that surveyed coverage was lower than reported coverage in both HDs, yet both were above the 65% threshold recommended by WHO. However, major variations of coverage have been noted among villages. Directly observed treatment appeared to have been well respected. The main challenges to increase coverage will be the systematic revisiting of households with absentees and the targeting of all households in each village.
Sections du résumé
Background & rationale
Burkina Faso has been implementing preventive chemotherapy against lymphatic filariasis since 2001. While 61 health districts (HDs) have stopped mass drug administration (MDA), transmission persists in 9 HDs despite good reported MDA coverage. To validate the reported coverage, an independent post-MDA survey was conducted in Tenkodogo and Fada N'Gourma HDs in September 2018.
Materials & methods
The study population consisted of all persons in the visited communities. The Coverage survey sample builder (CSSB) tool was used to calculate the sample size and to conduct the random selection of households. A total of 30 villages per HD were selected. The investigators were Ministry of Education agents and health workers not involved in MDA. Data were collected on smartphones through the KoBoCollect application regarding age, sex, drug ingestion (ivermectin + albendazole), adverse events, and whether respondents understood MDA guidelines. Stata Version 14 software was used for data analysis.
Results
A total of 3,741 individuals were surveyed, 53.3% were female and the median age was 14 years. Surveyed epidemiological coverage was 74% [95% CI: 72-76.1] in Fada N'Gourma and 79.1% [95% CI: 77.2-80.9] in Tenkodogo, compared to reported coverages of 82.6% and 83% respectively. Village-level coverage ranged from 32.9% to 100% in Fada N'Gourma and from 56.7% to 93.3% in Tenkodogo. In total, 99% of those treated said they had swallowed the drugs in front of the community drug distributor (CDD) and confirmed the use of dose poles. The main reasons for non-treatment were non-visitation of the compound by CDD (54%) and absences during MDA (43%). Results showed that surveyed coverage was lower than reported coverage in both HDs, yet both were above the 65% threshold recommended by WHO. However, major variations of coverage have been noted among villages. Directly observed treatment appeared to have been well respected.
Discussion & conclusion
The main challenges to increase coverage will be the systematic revisiting of households with absentees and the targeting of all households in each village.
Identifiants
pubmed: 36815181
doi: 10.48327/mtsi.v2i4.2022.174
pmc: PMC9940276
pii:
doi:
Substances chimiques
Albendazole
F4216019LN
Ivermectin
70288-86-7
Types de publication
English Abstract
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2022 SFMTSI.
Références
Parasit Vectors. 2016 Jan 27;9:29
pubmed: 26813098
Expert Opin Pharmacother. 2005 Feb;6(2):179-200
pubmed: 15757416
Clin Infect Dis. 2018 Jun 1;66(suppl_4):S260-S266
pubmed: 29860286
Am J Trop Med Hyg. 2020 Oct;103(4):1700-1710
pubmed: 32840202
Am J Trop Med Hyg. 2012 Aug;87(2):216-22
pubmed: 22855750
BMC Public Health. 2017 May 22;17(1):484
pubmed: 28532397